RVMD
Revolution Medicines, Inc.
There isn't enough reported data to score RVMD yet.
RVMD Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
RVMD's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
RVMD PE Valuation
RVMD has no meaningful PE right now: it lost money over the past year.
RVMD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect RVMD's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
RVMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$9.15 | -$4.08 |
| Q2 2026 | -$8.86 | -$4.46 |
| Q1 2026 | -$7.11 | -$3.21 |
| Q4 2025 | -$5.95 | -$2.48 |
| Q3 2025 | -$5.07 | -$1.39 |
| Q2 2025 | -$4.40 | -$0.67 |
| Q1 2025 | -$3.90 | -$0.06 |
| Q4 2024 | -$3.47 | +$0.39 |
RVMD lost $9.15 per share over the past year, a bigger loss than the year before.
RVMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2023 | $742K | -95% |
| Q2 2023 | $3.8M | -58% |
| Q1 2023 | $7M | -7.4% |
| Q4 2022 | $15.3M | +62% |
| Q3 2022 | $3.4M | +205% |
| Q2 2022 | $9.1M | +4.8% |
| Q1 2022 | $7.6M | -25% |
| Q4 2021 | $9.5M | +8.1% |
RVMD's revenue is growing: $198M last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -189% | N/A |
| Q4 2023 | -24256% | -23854 points |
| Q2 2023 | -2845% | -2164 points |
| Q1 2023 | -1072% | -307 points |
| Q4 2022 | -403% | +157 points |
| Q3 2022 | -2280% | +2548 points |
| Q2 2022 | -681% | -169 points |
| Q1 2022 | -765% | -396 points |
RVMD's operating margin was −189% last quarter, up 214 points from the same quarter a year ago.
RVMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$419.3M | -$208.7M |
| Q2 2026 | -$389.6M | -$160.4M |
| Q1 2026 | -$355.7M | -$158M |
| Q4 2025 | -$276.2M | -$136.7M |
| Q3 2025 | -$210.7M | -$76.7M |
| Q2 2025 | -$229.2M | -$98.6M |
| Q1 2025 | -$197.7M | -$34M |
| Q4 2024 | -$139.5M | -$16.6M |
RVMD has burned cash in almost every quarter: −$1.4B over the past year, against −$777M the year before.
RVMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +4.1M shares |
| 1 year | +14% | +25.7M shares |
| 3 years | +101% | +108M shares |
| 5 years | +193% | +142M shares |
| Available history | +489% | +178M shares |
RVMD has 215M diluted shares, up 14% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
RVMD Net Leverage
RVMD's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
RVMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.3 | Neutral |
| Stochastic | 22.2 | Neutral |
RVMD's weekly RSI is 49 (neutral) and its Stochastic is 22 (neutral).
RVMD PE vs Healthcare Sector
RVMD has no meaningful PE right now: it lost money over the past year.
RVMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $190.8 | 7.6% below |
| 20 week MA | $194.8 | 9.5% below |
| 50 week MA | $147.8 | 19% above |
| 100 week MA | $95.6 | 85% above |
| 200 week MA | $64.3 | 174% above |
RVMD has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 174% above its 200-week average.
RVMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $28.3 | $42.6 | +51% |
| 2021 | $42.6 | $27.6 | -35% |
| 2022 | $27.6 | $22.0 | -20% |
| 2023 | $22.0 | $28.7 | +30% |
| 2024 | $28.7 | $44.2 | +54% |
| 2025 | $44.2 | $80.8 | +83% |
| 2026 YTD | $80.8 | $176.4 | +118% |
RVMD has finished higher in four of the last six years, three of them by more than 50%. It's up 118% so far in 2026.